← Back to Search

Monoclonal Antibodies

BMS-986497 for Leukemia and Myelodysplastic Syndrome

Montreal, Canada
Phase 1
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Detectable levels of cluster of differentiation 33 (CD33) expression
Must not have
Acute Promyelocytic Leukemia
Clinically active central nervous system leukemia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to test the safety and effectiveness of a drug called BMS-986497 in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodyspl

See full description
Who is the study for?
This trial is for individuals with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants should have these conditions confirmed and not be responding to standard treatments. Specific eligibility criteria are not provided, but typically include factors like age, health status, and prior treatment history.Check my eligibility
What is being tested?
The study is testing BMS-986497's safety, tolerability, how the body processes it, its effectiveness in treating AML/MDS, and to establish the appropriate dosage. It's likely that participants will receive varying doses of BMS-986497 to find out which one works best with manageable side effects.See study design
What are the potential side effects?
While specific side effects of BMS-986497 are not listed here, common ones for cancer drugs may include nausea, fatigue, risk of infection due to low blood cell counts, bleeding or bruising easily from low platelets count and potential liver function changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have AML or MDS that has come back or didn't respond to treatment.
 show original
Select...
My cancer cells show CD33.
 show original
Select...
I have tried other treatments that didn't work for me.
 show original
Select...
I can care for myself and my organs are functioning well.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with Acute Promyelocytic Leukemia.
 show original
Select...
I have active leukemia in my brain or spinal cord.
 show original
Select...
I have an active cancer that is not blood-related.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part 2: Dose Expansion BMS-986497Experimental Treatment1 Intervention
Group II: Part 1: Dose Escalation BMS-986497Experimental Treatment1 Intervention

Find a Location

Closest Location:Local Institution - 0003· Montreal, Canada

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,727 Previous Clinical Trials
4,128,734 Total Patients Enrolled
~23 spots leftby Feb 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top